| DC48132 |
Bexotegrast
Featured
|
Bexotegrast is a potent inhibitor of ανβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) (extracted from patent WO2020210404A1, compound 5). |
|
| DC48139 |
NVS-BET-1
Featured
|
NVS-BET-1 is a BET bromodomain inhibitor that regulates keratinocyte plasticity. |
|
| DC48154 |
SUN B8155
Featured
|
SUN B8155, a non-peptide agonist of calcitonin (CT) receptor, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis. |
|
| DC48164 |
Aceclidine
Featured
|
Aceclidine is a modulator of M3 muscarinic acetylcholine receptor. Aceclidine is a cycloplegic agent, a surfactant, a tonicity adjustor and optionally a viscosity enhancer and an antioxidant. Aceclidine has the potential for the research of disorders such as refractive errors of the eye, xerostomia, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, and esotropia (extracted from patent US20150290125A1/US20110091459A1). |
|
| DC48169 |
DS34942424
Featured
|
DS34942424 is an orally potent analgesic without mu opioid receptor agonist activity. |
|
| DC48172 |
BAY-6672
Featured
|
BAY-6672 is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM. |
|
| DC48191 |
Cipepofol
Featured
|
Cipepofol (HSK3486), a sedative-hypnotic agent, is a gamma-aminobutyric acid (GABA) receptor potentiator. |
|
| DC48215 |
Zagociguat
Featured
|
Zagociguat is the stimulator of soluble guanylate cyclase. Zagociguat increases nitric oxide (NO) signaling leading to an increase in cyclic guanosine monophosphate production. Zagociguat has the potential for the research of noncentral nervous system (CNS) disorders. |
|
| DC48216 |
NLG802
Featured
|
NLG802 is a prodrug of indoximod, an orally active indoleamine 2,3-dioxygenase (IDO) inhibitor. |
|
| DC48226 |
ONO-8430506
Featured
|
ONO-8430506 is an orally bioavailable and potent autotaxin (ATX)/ENPP2 inhibitor with the IC90 of 100 nM for ATX activity in mouse plasma. |
|
| DC48230 |
Sterculic acid
Featured
|
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM. |
|
| DC48250 |
MLT-985
Featured
|
MLT-985 is a highly selective allosteric MALT1 inhibitor with an IC50 value of 3 nM. |
|
| DC48270 |
Bocidelpar
Featured
|
Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b). |
|
| DC48291 |
ATX-002
Featured
|
ATX-002 is a property-tunable lipid for RNA drug delivery. |
|
| DC48292 |
Minzasolmin
Featured
|
Minzasolmin is an alpha-synuclein oligomerization inhibitor. |
|
| DC48293 |
Linvencorvir
Featured
|
Linvencorvir is an antiviral agent. |
|
| DC48302 |
VL-6
Featured
|
VL-6 can be used in the synthesis of biomimetic nanomaterials which for delivery of therapeutic, diagnostic, or prophylactic agents. |
|
| DC48324 |
Mitiperstat(AZD4831)
Featured
|
Mitiperstat is the potent inhibitor of myeloperoxidase (MPO). Mitiperstat is particularly useful in the research of prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions (extracted from patent US20160152623A1). |
|
| DC48326 |
ELOVL1-IN-3
Featured
|
ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)[1]. |
|
| DC48330 |
680C91
Featured
|
680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease. |
|
| DC48349 |
SP-8356
Featured
|
SP-8356, an anti-inflammatory synthetic verbenone derivative, is a potent, orally active cluster of differentiation 147 (CD147) inhibitor. SP-8356 inhibits CD147-cyclophilin A (CypA) interaction and reduces MMP-9 activity. SP-8356 exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects[1][2][3]. |
|
| DC48359 |
Bezuclastinib
Featured
|
Bezuclastinib (PLX 9486; CGT9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001
|
|
| DC48360 |
GNF2133
Featured
|
GNF2133 is a selective DYRK1A inhibitor with an IC50 value of 6 nM. |
|
| DC48363 |
DMPQ dihydrochloride
Featured
|
DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC50 of 80 nM. |
|
| DC48364 |
Sovleplenib
Featured
|
Sovleplenib is a highly potent inhibitor of spleen tyrosine kinase (Syk), derived from the innovative research disclosed in patent WO2012167733 A1. This compound demonstrates significant potential in modulating Syk-mediated signaling pathways, offering a promising therapeutic approach for conditions where Syk activity plays a critical role. Its development underscores the ongoing advancements in targeted kinase inhibition, providing a valuable tool for both research and potential clinical applications in immune-related and inflammatory diseases. |
|
| DC48365 |
RO7185876
Featured
|
RO7185876 is a potent and selective gamma secretase modulator as a potential treatment for Alzheimer's disease. |
|
| DC48369 |
AGB1
Featured
|
AGB1 is a fast, highly selective, and potent bump-and-hole (B&H)-PROTAC degrader for BromoTag. AGB1 exhibits degradation for Ab:Brd4BD2 L387A and Ab: BromoTag-Brd2 with pDC50s of 7.8 and 7.9. AGB1 exhibits binary affinity to VHL (Kd=125 nM). AGB1 exhibits favorable pharmacokinetic profile in mice with the DC50, 6 h of ∼13 nM. |
|
| DC48373 |
dTAGV-1 TFA
Featured
|
dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12F36V fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12F36V-Nluc in vivo. |
|
| DC48395 |
ACT-1004-1239
Featured
|
ACT-1004-1239 is a potent, selective, orally available CXCR7 antagonist with an IC50 value of 3.2 nM. |
|
| DC48401 |
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
Featured
|
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate for ADC with potent antitumor activity by using TLR7/8 agonist 4, linked via the cleavable ADC linker hydroxy-PEG10-acid.
|
|
